Stem Cells: Therapeutic Approaches and Pharmaceutical Screening in Cardiovascular Diseases Ph.Menasché Department of Cardi...
Stem Cells in France: Research and Therapy <ul><li>Strengths  </li></ul><ul><li>- Long-standing experience in cell therapy...
Embryonic Stem Cells in France <ul><li>The Specific Regulatory Environment of ESC  </li></ul><ul><li>- Permission to work ...
Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective :  Myocardial regeneration </li></ul...
Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective :  Myocardial regeneration </li></ul...
Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective :  Myocardial regeneration </li></ul...
Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells shou...
Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells shou...
Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells shou...
Induced Pluripotent Stem Cells   Yamanaka S Cell 2009;137:13-17.
Induced Pluripotent Stem Cells Cell Stem Cell 2010;6:407-11. <ul><li>Assets of France </li></ul><ul><li>Development of iPS...
Upcoming SlideShare
Loading in …5
×

14 rencontres biomédicale LIR Philippe Menasché

750 views

Published on

2ND INTERNATIONAL RESEARCH MEETING
4 JUNE 2010- HÔTEL DE MARIGNY PARIS

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
750
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

14 rencontres biomédicale LIR Philippe Menasché

  1. 1. Stem Cells: Therapeutic Approaches and Pharmaceutical Screening in Cardiovascular Diseases Ph.Menasché Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou & INSERM U633, Paris
  2. 2. Stem Cells in France: Research and Therapy <ul><li>Strengths </li></ul><ul><li>- Long-standing experience in cell therapy </li></ul><ul><li>- Current efforts to streamline the regulatory process for implementing clinical trials </li></ul><ul><li>- Tight interactions between basic science laboratories and clinical departments facilitating translational research </li></ul>
  3. 3. Embryonic Stem Cells in France <ul><li>The Specific Regulatory Environment of ESC </li></ul><ul><li>- Permission to work on human ESC under specific approval by a dedicated Agency </li></ul><ul><li>- To date, 31 approved research teams totalling </li></ul><ul><li>39 imported and 24 on-site derived hESC lines </li></ul><ul><li>- Pending reassessment of the Bioethical Law with low probability of a backward shift </li></ul>
  4. 4. Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective : Myocardial regeneration </li></ul><ul><li>- Preclinical studies of skeletal myoblasts in rodents and sheep (1995-2000) </li></ul>Engraftment of myoblasts in an infarcted sheep heart
  5. 5. Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective : Myocardial regeneration </li></ul><ul><li>- Clinical trials (myoblast Tx + CABG) : </li></ul><ul><li>First in-man Phase I (2000-2001) : 10 patients </li></ul><ul><li>Phase II (2002-2006) : 97 patients </li></ul>MG Biotherapeutics Multicentric Randomized Controlled Dose ranging Double blind Myoblast Autologous Grafting in Ischemic Cardiomyopathy Myoblast injections in infarcted myocardium
  6. 6. Cell Transplantation in Heart Failure: Soon Ready for Prime Time? <ul><li>- Objective : Myocardial regeneration </li></ul><ul><li>- Shift towards human ESC-derived cardiac progenitors (2005- ongoing) </li></ul><ul><li>Preclinical studies in rodents and nonhuman primates </li></ul><ul><li>Translational studies in preparation for a pilot phase I trial (scale-up under GMP conditions, extensive safety testing, validation of preclinical runs, development of a cell-seeded biomaterial) </li></ul>Blin et al. J Clin Invest 2010; 120:1125-39.
  7. 7. Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells should be tailored to the primary clinical indication </li></ul><ul><li>- Upgrading cells to a « product » may require allogeneic tissue sources </li></ul><ul><li>- Cell engraftment (retention + survival) rates must be optimized </li></ul>
  8. 8. Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells should be tailored to the primary clinical indication </li></ul><ul><li>- Upgrading cells to a « product » may require allogeneic tissue sources </li></ul><ul><li>- Cell engraftment (retention + survival) rates must be optimized </li></ul>
  9. 9. Therapeutic Use of Stem Cells <ul><li>Lessons Drawn From the Early Experience </li></ul><ul><li>- The choice of cells should be tailored to the primary clinical indication </li></ul><ul><li>- Upgrading cells to a « product » may require allogeneic tissue sources </li></ul><ul><li>- Cell engraftment (retention + survival) rates must be optimized </li></ul>
  10. 10. Induced Pluripotent Stem Cells Yamanaka S Cell 2009;137:13-17.
  11. 11. Induced Pluripotent Stem Cells Cell Stem Cell 2010;6:407-11. <ul><li>Assets of France </li></ul><ul><li>Development of iPS technology based on </li></ul><ul><li>previous ESC experience </li></ul><ul><li>Large patient cohorts </li></ul><ul><li>Planning to launch government-funded </li></ul><ul><li>Technology Research Institutes in partnership </li></ul><ul><li>with private biotech/pharma companies </li></ul>

×